|
D6a: implant date unknown h6: neither the device nor films of applicable imaging studies were returned to the manufacturer for evaluation.Therefore, we are unable to determine the definitive cause of the reported event.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Information was received from a healthcare professional (hcp) via a medtronic representative regarding a patient with clinical id (b)(4) and study id (b)(4).It was reported that the patient completed a ct scan on (b)(6) 2022.The surgeon reviewed the same on (b)(6) 2022 and noticed left-sided ectopic bone growth which could potentially be impacting the patient's left leg pain.The patient's implants are intact and she appears to be solidly fused in the interbody space.The patient discussed potentially trying a transforaminal steroid injection at the l5-s1 segment with the surgeon.Diagnostics: mri without contrast on (b)(6) 2022 ; results- solidly fused in the interbody space; left- sided ectopic bone growth.Sponsor assessment: sponsor assessed not related to study procedure ; possibly related to tlif grafting material ; unlikely related to capstone peek spinal system and posterior supplemental fixation system.Primary diagnosis: stenosis update received: description- left-sided ectopic bone growth at l5-s1 outcome status- unknown narrative- ae involves level l5-s1 severity of ae- moderate site related assessment- unlikely related to capstone peek and tlif grafting material, not related to posterior supplemental fixation system, possibly related to study procedure (l5-s1 tlif) update received: sponsor assessment- sponsor assessed as possibly related to study procedure ; possibly related to tlif grafting material ; unlikely related to capstone peek spinal system and posterior supplemental fixation system.Additional information was received.Investigator assessment- possibly related to the tlif grafting material update received (same as previous): site related assessment- possibly related to tlif grafting material.Update received: the number of consecutive levels (from l2-s1) that will be treated: 1 most recent date the subject had either a ct or mri: on b)(6) 2021 medication history: subject has used non-narcotic medications, muscle relaxants, non-narcotic over the counter pain medications, and strong narcotic medications in the last 7 days date of hospital admission: on (b)(6)2021 date of hospital discharge: on (b)(6) 2021 date of follow up visit: on (b)(6)2021, (b)(6) 2022, outcome status: not recovered/ not resolved update received: additional surgical procedure date: on (b)(6) 2023 details surgical procedure: left l5/s1 foraminotomy the additional surgical procedure involves l5-l6, l6-s1.Update received: interventions: surgical treatment the additional surgical procedure involves l5-s1.Outcome status: recovering/ resolving update received: additional surgery was performed.Site related assessment for additional surgery- unlikely related to capstone peek spinal system and posterior supplemental fixation system, probably related to tlif grafting material and study procedure (tlif with infuse) update received: sponsor assessment for additional surgery- probably related to the tlif grafting material.No device deficiencies have been submitted in the tlif study update received: intervention: ae resulted in hospitalization from (b)(6) 2023 site seriousness assessment: medical intervention severity of ae: severe update received: ae: l5-s1 radiculopathy outcome status; recovering/resolving (no date of resolution) update received: intervention: patient was administered with a solution of 10mg dexamethasone pf 10mg/m and 4ml sodium chloride (pf) 0.9% was divided equally among the affected levels (l5-s1) and injected on (b)(6) 2023.After completion of the injection, the needle was flushed.Update received: site seriousness assessment: hospitalization (y) ; medical intervention (n) update received: sponsor assessment (cec): possibly related to procedure, tlif grafting material, interbody device.Not related to posterior supp.Fixation.Underwent left l5/s1 foraminotomy.
|